Secukinumab in pregnancy?

What are the implications for a pregnant woman taking Secukinumab?

Secukinumab, a medication used to treat conditions like plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis, has a complex relationship with pregnancy. According to the manufacturer, there are limited human studies on the use of Secukinumab during pregnancy, and the current evidence is primarily based on case reports and animal studies [1].

What have we learned from animal studies?

Animal studies have provided insights into the potential risks associated with Secukinumab during pregnancy. In rats and rabbits, the drug was shown to be associated with an increased risk of fetal malformations, growth restrictions, and stillbirths, particularly at high doses or during the period of organogenesis [2].

What about human case reports?

There are scattered reports on the use of Secukinumab during pregnancy, but these are limited in number and do not provide a clear picture of the drug's safety or efficacy in pregnant women [3]. In general, the reports suggest that pregnant women taking Secukinumab may experience premature birth, low birth weight, and other pregnancy complications, although the exact risk is difficult to quantify.

How should a pregnant woman manage her treatment regimen with Secukinumab?

Given the uncertain risks associated with Secukinumab during pregnancy, healthcare providers may recommend adjusting the treatment regimen or switching to a alternative therapy altogether [4]. Pregnant women should consult their healthcare provider before making any changes to their treatment plan. They can discuss the potential risks and benefits of continued treatment with Secukinumab and explore options for managing their condition safely during pregnancy.

When can women with plaque psoriasis expect their treatment patents to expire?

The patents for Secukinumab expire in various countries at different times. According to the patent watch tool DrugPatentWatch.com, the European patent for Secukinumab will expire in 2032, while the US patent is already expired [5].

Who are the main manufacturers of Secukinumab?

Secukinumab is developed by Novartis and Cosentyx manufacturer Novartis has partnered with several other companies to commercialize this drug, including the company Novartis partnered with for Cosentyx which is Novartis themselves